GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » Dividends per Share

ME Therapeutics Holding (XCNQ:METX) Dividends per Share : C$0.00 (TTM As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding Dividends per Share?

ME Therapeutics Holding's dividends per share for the three months ended in Feb. 2024 was C$0.00. Its dividends per share for the trailing twelve months (TTM) ended in Feb. 2024 was C$0.00. Its Dividend Payout Ratio for the three months ended in Feb. 2024 was 0.00. As of today, ME Therapeutics Holding's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.


ME Therapeutics Holding Dividends per Share Historical Data

The historical data trend for ME Therapeutics Holding's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding Dividends per Share Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
Dividends per Share
- -

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
Dividends per Share Get a 7-Day Free Trial - - - - -

Competitive Comparison of ME Therapeutics Holding's Dividends per Share

For the Biotechnology subindustry, ME Therapeutics Holding's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ME Therapeutics Holding's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ME Therapeutics Holding's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where ME Therapeutics Holding's Dividend Yield % falls into.



ME Therapeutics Holding Dividends per Share Calculation

Dividends paid to per common share.


ME Therapeutics Holding  (XCNQ:METX) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

ME Therapeutics Holding's Dividend Payout Ratio for the quarter that ended in Feb. 2024 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Feb. 2024 )/ EPS without NRI (Q: Feb. 2024 )
=0/ -0.01
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ME Therapeutics Holding Dividends per Share Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ME Therapeutics Holding (XCNQ:METX) Business Description

Comparable Companies
Traded in Other Exchanges
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines